Robert Azelby
CIK 1656998 · President & CEO · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.03M
Companies
10
Total Filings
45
Lifetime Open-Market Net
-$14.08M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADCT | Director | 112,805 | $1.05 | $118.4K | -$20.2K | 5 | 2026-06-03 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 3 | 2026-05-05 |
| CAH | Director | 4,085 | $223.85 | $914.4K | $0 | 3 | 2025-11-06 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Director | — | $40.39 | — | $0 | 2 | 2023-08-11 |
| Climb Bio, Inc. (ELYM) Delisted | President & CEO | — | $5.11 | — | $0 | 2 | 2022-11-02 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | — | $0.08 | — | $0 | 4 | 2021-06-11 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 3,718 | — | — | $0 | 3 | 2020-10-23 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | President and CEO | — | — | — | $0 | 3 | 2019-04-25 |
| Juno Therapeutics, Inc. (JUNO) Delisted | EVP & Chief Commercial Officer | 0 | — | — | -$14.06M | 16 | 2018-03-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | — | — | — | $0 | 2 | 2017-06-13 |
Recent Filings · Page 4 of 5
45 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-09 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | −2,700 | -$454.4K | EDGAR |
| 2018-02-02 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | +25,639 | -$141.8K | EDGAR |
| 2018-01-24 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | — | -$3.54M | EDGAR |
| 2018-01-19 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | — | -$1.38M | EDGAR |
| 2017-12-20 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −1,816 | -$81.6K | EDGAR |
| 2017-11-09 | Juno Therapeutics, Inc. (JUNO) Delisted | Tax (F) | −684 | -$38.3K | EDGAR |
| 2017-11-03 | Juno Therapeutics, Inc. (JUNO) Delisted | Mixed | — | -$197.7K | EDGAR |
| 2017-10-20 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | +35,893 | $0 | EDGAR |
| 2017-09-14 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,850 | -$577.6K | EDGAR |
| 2017-08-31 | Juno Therapeutics, Inc. (JUNO) Delisted | Sell (S) | −12,869 | -$514.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.